MK0767 Glipizide Comparator Cardiac Safety Study
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Mellitus, Type 2
Intervention: MK0767 (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2
Diabetes.
This is an early phase trial and some specific protocol information is in progress and not
publicly available at this time. (Full information is available to trial participants).
Clinical Details
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 21 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- You are taking at least one medication for high blood sugar
- Age 21 to 80
Exclusion Criteria:
- History of Type 1 Diabetes Mellitus
- Currently on estrogen replacement therapy regimen
- Currently on a weight loss program with ongoing weight loss or taking medications for
weight loss
- Having surgery 30 days before starting the study
- Have taken any other investigational drug in the past 90 days
- Have Hepatitis B or C
- Active liver or gallbladder disease
Locations and Contacts
Additional Information
Starting date: November 2002
Ending date: November 2004
Last updated: October 11, 2007
|
